Orchestra BioMed Holdings, Inc.

Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) is a biomedical company focused on cardiovascular medical devices and neuromodulation therapies that became publicly traded through a de-SPAC merger with Health Assurance Acquisition Corp, a healthcare-focused blank-check vehicle sponsored by Health Assurance Holdings LLC that completed its IPO in 2020. The business combination closed in January 2023, listing Orchestra BioMed and its pipeline — including its BackBeat cardiac neuromodulation program — on Nasdaq. The company filed an 8-K current report with the SEC on June 23, 2026, disclosing a material corporate event. For full filing history, sponsor data, and deal analytics on OBIO, sign up for a SpacDesk account today.